I’ve been following it, maybe a little too much.
- 100x San-HQ production capacity at the end of the last quarter.
- San 2.0 launched, with sales starting at the end of Q3, enabling a broader customer base.
- Lab-a-porter new distributor.
- New MDx customer.
- Virus X report completed - behind paywall.
- Arctic products starting to appear on Chinese websites.
- COVID-19 testing has not decreased.
- Two large cGMP auditors mentioned in the last quarter.
- Institutional ownership has increased.
- Reithera’s funding issues complicate and delay vaccine approval. Fortunately, those who have received two vaccine doses have been granted a green pass with a special permit. Speculation that Mexico will be involved in the next phase.
- There has been speculation about another COVID-19 vaccine manufacturer, but the name has not been released (Sanofi has appeared in Norwegian forums, speculation).
- Goal to add to the portfolio within 2-3 years. Personal suspicion is that the company will also start to attract potential buyers.
- Global enzyme market growth expected to grow by 9.4% by 2027 (CAGR), earlier forecast 7%.
- Pareto weakened its recommendation from 135 NOK to 133 NOK.
- Has the COVID-19 situation complicated sales or new agreements?
- Cyclicality of orders?
Sources:
https://lab-a-porter.com/2021/06/novel-enzymes-from-the-arctic/
Generally, people have rather modest expectations, and systematically downplay/underestimate COVID-19 revenues. Good quarterly results have come from customers and similar companies.
In this company’s case, too, trust your own research and don’t listen to what others say.